Reactive Oxygen Species 1 Positive Non Small Cell Lung Cancer — Patent Landscape

Aggregated US Orange Book patent estate across every approved drug for reactive oxygen species 1 positive non small cell lung cancer. 28 active patents protecting 1 drugs from 1+ originators. First major cliff: 2028. Daily refresh.

1
Approved drugs
28
Active US patents
51/100
Avg vulnerability
$300M
Annual revenue covered

Originators in Reactive Oxygen Species 1 Positive Non Small Cell Lung Cancer

Companies holding active patents on drugs approved for this indication. Click through to each company's full patent dashboard.

Roche 28 patents

Cliff calendar — next 15 years

Patent expiries per year across all drugs treating reactive oxygen species 1 positive non small cell lung cancer. Each bar = one year. Y-axis scaled to peak year (10 patents).

10
28
2
32
4
33
4
35
4
37
4
38

Approved drugs ranked by patent estate

Drug Originator Active patents Avg vuln Revenue First cliff
Rozlytrek
entrectinib
 Roche 28 51 $300M 2028-07-08

Most attackable patents

Highest vulnerability scores in the indication — paragraph IV / IPR / design-around candidates.

Patent Drug Type Vuln Expiry
9616059 Rozlytrek method of use 75 2028-07-08
9616059 Rozlytrek method of use 75 2028-07-08
8673893 Rozlytrek method of use 75 2028-07-08
9255087 Rozlytrek method of use 75 2028-07-08
8673893 Rozlytrek method of use 75 2028-07-08
9255087 Rozlytrek method of use 75 2028-07-08
9649306 Rozlytrek method of use 62 2033-05-22
9649306 Rozlytrek method of use 62 2033-05-22
10231965 Rozlytrek method of use 62 2035-02-17
10231965 Rozlytrek method of use 62 2035-02-17

Strongest defences

Lowest vulnerability scores — pillars of the indication's IP fortress.

Patent Drug Type Vuln Expiry
9085565 Rozlytrek composition of matter 4 2033-05-22
9085565 Rozlytrek composition of matter 4 2033-05-22
8299057 Rozlytrek composition of matter 10 2032-03-10
8299057 Rozlytrek composition of matter 10 2032-03-10
9029356 Rozlytrek composition of matter 17 2028-07-08
9029356 Rozlytrek composition of matter 17 2028-07-08
10398693 Rozlytrek formulation 42 2038-07-18
10398693 Rozlytrek formulation 42 2038-07-18
11253515 Rozlytrek formulation 50 2038-07-18
11253515 Rozlytrek formulation 50 2038-07-18

Related